Coxsackieviral infection of the heart is an important cause of cardiomyopathy in children and adults. However, little is known of the innate signaling mechanisms within the cardiac myocytes that control viral infection. A better understanding of these mechanisms may allow design of novel therapeutic strategies for viral heart disease. Recently, we have shown that inhibition of Janus kinase (JAK)- signaling transducer and activator of transcription (STAT) in the cardiac myocyte by expression of SOCS 1 has a marked effect on viral replication and viral-mediated cytopathic effects. Disruption of interferon alpha/beta receptors had no effect and disruption of interferon-gamma receptors had minimal effect on early viral replication in the heart. We, therefore, hypothesize that other, non-interferon mediated innate immune mechanisms are important within the cardiac myocyte to combat viral infection. These could include signaling through the glycoprotein (gp) 130 that also activates JAK-STAT signaling. We, therefore, propose the following specific aims: 1) Determine in CVB3 infected mice whether gp130, IFN-gamma signaling, or both are important for a) the induction of JAK-STAT-SOCS signaling in the heart and b) the innate immune defense against viral infection. 2) Identify mechanisms related to viral infection and replication by which forced expression of SOCS1 in the cardiac myocyte induces a marked cytopathic effect following CVB3 infection and determine whether transgenic SOCS3 expression will also affect the innate immune response in a manner similar to that observed in SOCS1 transgenic mice. 3) Determine the effect of cardiac-specific knockout of SOCS1 and SOCS3 on JAK-STAT signaling in cardiac myocytes and the cardiomyopathy associated with CVB3 infection.
These aims will provide a novel insight into the mechanisms by which JAK-STAT-SOCS activation within the cardiac myocyte regulates the innate anti-viral response.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Cardiovascular and Pulmonary Research A Study Section (CVA)
Program Officer
Schwartz, Lisa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Internal Medicine/Medicine
Schools of Medicine
La Jolla
United States
Zip Code
Yajima, Toshitaka; Knowlton, Kirk U (2009) Viral myocarditis: from the perspective of the virus. Circulation 119:2615-24
Dorner, Andrea; Xiong, Dingding; Couch, Kellie et al. (2004) Alternatively spliced soluble coxsackie-adenovirus receptors inhibit coxsackievirus infection. J Biol Chem 279:18497-503
Badorff, Cornel; Knowlton, Kirk U (2004) Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med Microbiol Immunol 193:121-6
Zhao, Xiaohong; Lamphear, Barry J; Xiong, Dingding et al. (2003) Protection of cap-dependent protein synthesis in vivo and in vitro with an eIF4G-1 variant highly resistant to cleavage by Coxsackievirus 2A protease. J Biol Chem 278:4449-57
Xiong, Dingding; Lee, Gil-Hwan; Badorff, Cornel et al. (2002) Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med 8:872-7
Wessely, R; Klingel, K; Knowlton, K U et al. (2001) Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation 103:756-61
Badorff, C; Berkely, N; Mehrotra, S et al. (2000) Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J Biol Chem 275:11191-7
Badorff, C; Fichtlscherer, B; Rhoads, R E et al. (2000) Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy. Circulation 102:2276-81
Lee, G H; Badorff, C; Knowlton, K U (2000) Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy. Circ Res 87:489-95
Badorff, C; Lee, G H; Knowlton, K U (2000) Enteroviral cardiomyopathy: bad news for the dystrophin-glycoprotein complex. Herz 25:227-32